Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (Symbol: LTRN) is at the forefront of innovation in the realm of cancer treatment, striving to deliver the most effective therapies to patients who are poised to benefit the most. The company employs a pioneering precision medicine approach to cancer treatment, leveraging biomarker-based genetic screening to identify and treat patients who would derive the greatest benefit from their drugs. This method not only reduces the cost of drug development but also expedites the time to market.
Lantern Pharma's core business revolves around its proprietary artificial intelligence (AI) and machine learning (ML) platform, RADR. The RADR platform assimilates oncology-focused data points and utilizes advanced ML algorithms to address complex, billion-dollar challenges in cancer drug development. This innovative platform has significantly accelerated the company's growing pipeline of precision therapies, with input from world-class scientific advisors and collaborators.
In addition to its in-house development, Lantern Pharma adopts a strategic approach by acquiring or partnering with promising drug and diagnostic companies. This strategy is aimed at advancing personalized medicine programs for cancer patients, thus broadening the company's impact in the oncology space.
With a commitment to transforming the cost, pace, and timeline of oncology drug discovery and development, Lantern Pharma continues to make strides in the development of precision therapies. The company's recent achievements and ongoing projects underscore its potential to revolutionize cancer treatment and deliver significant value to both patients and stakeholders.
Lantern Pharma (NASDAQ: LTRN) has announced the first patient dosing in Japan for its Phase 2 HARMONIC™ clinical trial of LP-300 in never-smoker NSCLC patients. The trial, now expanded to ten sites across Japan and Taiwan, focuses on patients who have progressed after TKI treatment. Initial results from the U.S. trial showed an 86% clinical benefit rate and 43% objective response rate among the first seven patients. The expansion is significant as NSCLC in never-smokers occurs 2-3 times more frequently in East Asian countries, with Japan reporting 33-40% of new lung cancer cases in never-smokers.
Lantern Pharma reported Q3 2024 financial results and clinical updates. The company's LP-300 Harmonic™ Trial showed an 86% clinical benefit rate in initial patients and expanded to Japan and Taiwan. Phase 1 trials for LP-184 and LP-284 continue with no dose-limiting toxicities. LP-184 received FDA Fast Track Designation for Glioblastoma. Financial highlights include $28.1 million in cash and equivalents, R&D expenses of $3.7 million, and a net loss of $4.5 million ($0.42 per share). The company maintains three active clinical trials and is advancing its AI-guided precision-oncology drug candidates.
Starlight Therapeutics, a subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), announced the formation of its Scientific Advisory Board (SAB) to support the development of STAR-001 for CNS and brain tumors. The inaugural SAB includes four distinguished experts: Dr. Mitchel S. Berger from UCSF, Dr. Lisa M. DeAngelis from Memorial Sloan Kettering, Dr. Stuart Grossman from Johns Hopkins Kimmel Cancer Center, and Dr. John Laterra from Johns Hopkins. These experts will provide strategic guidance for developing treatments targeting both adult and pediatric CNS cancers.
Lantern Pharma (NASDAQ: LTRN), an AI-driven cancer therapy development company, will host its third quarter 2024 operating and financial results webcast on Thursday, November 7, at 4:30 p.m. ET. CEO Panna Sharma and management will discuss Q3 2024 results ending September 30, provide guidance on upcoming milestones, clinical trials, and developments of their proprietary RADR® AI and machine learning platform. A replay will be available on the company's investor relations website after the call.
Lantern Pharma (NASDAQ: LTRN), an AI-focused company developing cancer therapies, announced its participation in the upcoming ThinkEquity Conference. The presentation is scheduled for Wednesday, October 30, 2024, at 10:30 a.m. ET and will take place at the Mandarin Oriental in New York, NY. The company's management will be available for one-on-one meetings during the conference. The event can be accessed through provided webcast and registration links, offering investors an opportunity to learn about Lantern's innovative approach to oncology drug discovery and development.
Lantern Pharma (NASDAQ: LTRN), an AI-focused oncology drug development company, announced two public webinars in October. The first, on October 28th, features CEO Panna Sharma discussing AI's role in developing therapies for brain and childhood cancers. The second, on October 30th, hosts Actuate Therapeutics' COO Andrew Mazar, highlighting how Lantern's AI platform accelerated the development of Actuate's drug candidate, Elragllusib.
The webinars will showcase RADR®, Lantern's AI platform, and its impact on advancing their portfolio and collaborators' work. Lantern will detail how big data and AI are leveraged to develop LP-184 and LP-284, currently in Phase 1 trials. The company will also discuss their blood-brain-barrier penetrability algorithm, important for LP-184's development in CNS cancer indications, including glioblastoma.
Lantern Pharma has received four Rare Pediatric Disease Designations and the FDA's Fast Track Designation for glioblastoma, underlining their progress in addressing critical unmet needs in oncology.
Lantern Pharma's investigational drug-candidate, LP-184, has received Fast Track Designation from the FDA for the treatment of Glioblastoma (GBM). This designation is designed to expedite FDA review of important new drugs for serious conditions with unmet medical needs. GBM affects over 13,000 U.S. adults annually and approximately 300,000 globally. LP-184, to be developed as STAR-001 by Starlight Therapeutics (a Lantern Pharma subsidiary), has the potential to be the first new GBM drug in over 20 years.
LP-184 is currently in a Phase 1A clinical trial evaluating its safety and tolerability in various solid tumors, including GBM. The drug was optimized using Lantern's AI platform, RADR®, which has over 100 billion data points and aids in cancer therapy discovery and development. A Phase 1b/2a clinical trial for recurrent GBM is targeted to start in late 2024/early 2025.
Lantern Pharma (NASDAQ: LTRN) has received three rare pediatric disease designations (RPDD) from the FDA for its drug candidate LP-184 in malignant rhabdoid tumors, rhabdomyosarcoma, and hepatoblastoma. This brings the total RPDDs for LP-184 to four, including a previous designation for atypical teratoid rhabdoid tumors. The efficacy of LP-184 was demonstrated through tumor regression and extended event-free survival in models developed by the NCI-supported Pediatric Preclinical Testing Program.
RPDDs can lead to Priority Review Vouchers upon FDA marketing approval, which can expedite future drug reviews or be sold for significant sums. LP-184 is currently in a Phase 1A clinical trial enrolling 50-60 patients across various solid tumors. Lantern Pharma aims to use AI and data-driven approaches to revolutionize cancer drug development, potentially reducing costs and accelerating timelines for new therapies.
Lantern Pharma (NASDAQ: LTRN) reported Q2 2024 financial results and business updates. Key highlights include:
1. Preliminary data from LP-300 Harmonic™ Trial showed 86% clinical benefit rate in initial 7-patient cohort.
2. Phase 1 trials for LP-184 and LP-284 progressing with no dose-limiting toxicities.
3. Launched AI-driven collaboration with Oregon Therapeutics for XCE853 development.
4. Starlight Therapeutics advancing Phase 1B/2 trial for STAR-001 in recurrent GBM.
5. Q2 2024 financials: $33.3M cash position, $3.9M R&D expenses, $1.5M G&A expenses, $4.96M net loss ($0.46 per share).
6. RADR® AI platform continues to expand in size and capabilities.
Lantern Pharma (NASDAQ: LTRN) announced promising preclinical results for LP-184, demonstrating synergy with checkpoint inhibitors and the ability to resensitize tumors non-responsive to Anti-PD1 therapies. Key findings include:
1. LP-184 potentiates anti-PD1 response in a mouse model of triple negative breast cancer (TNBC) resistant to immunotherapy.
2. It can transform 'cold' tumors into 'hot' tumors by modulating T cell activity and inducing replication stress response defects.
3. LP-184 reshapes the tumor microenvironment by reducing M2 macrophages associated with tumor drug resistance.
4. Combined with anti-PD1, LP-184 showed greater anti-tumor response than monotherapies in mouse TNBC tumors.
LP-184 is currently in a Phase 1 trial for advanced recurrent solid tumors. This research supports Lantern's AI-driven hypothesis on LP-184's potential to synergize with PD1 and PDL1 drugs, potentially improving cancer treatment outcomes.
FAQ
What is the current stock price of Lantern Pharma (LTRN)?
What is the market cap of Lantern Pharma (LTRN)?
What does Lantern Pharma Inc. specialize in?
What is the RADR platform?
How does Lantern Pharma's approach reduce drug development costs?
What is the company's strategy for growth?
How does Lantern Pharma use AI in drug development?
Who are the key collaborators with Lantern Pharma?
What are some of Lantern Pharma's recent achievements?
Why is precision medicine important in cancer treatment?
How does Lantern Pharma's strategy benefit cancer patients?
What is the significance of biomarker-based genetic screening?
